Professor Anthony Chalmers

  • Chair of Clinical Oncology (Clinical Trials Research)

telephone: 01413306426
email: Anthony.Chalmers@glasgow.ac.uk

Research interests

Glioblastoma is the commonest and most aggressive primary brain tumour and is often refractory to conventional cancer treatments. The ultimate aim of our research group is to improve outcomes for patients with these tumours by overcoming their inherent resistance to radiotherapy and chemotherapy.

Much of our work has focused on the DNA repair protein poly(ADP-ribose) polymerase, commonly known as PARP. Drugs that inhibit PARP increase the sensitivity of tumour cells to radiotherapy and to chemotherapy agents such as temozolomide. We are currently developing a series of clinical trials to test whether PARP inhibitors can be safely and effectively combined with radiotherapy and chemotherapy in patients with glioblastoma.

Current and future work will also investigate the effect of the tumour microenvironment on radiation responses of glioblastoma cells. In order to do this we are developing a novel in vitro cell culture system that recapitulates some of the key features of the glioblastoma microenvironment.

Biography

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • PARADIGM-2: Olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in newly diagnosed glioblastoma stratified by MGMT status: 2 parallel phase I studies
    Cancer Research UK
    2016 - 2020
     
  • Modulating the p53/mdm2 axis to enhance outcomes of radiotherapy for head & neck cancer: tumour and normal tissue studies in vitro and in vivo
    British Association of Head & Neck Oncologists
    2016 - 2017
     
  • Overcoming treatment resistance by activating cell death in mesothelioma
    British Lung Foundation
    2016 - 2018
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2016 - 2017
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2016 - 2017
     
  • Identification and validation of novel targets for overcoming radiation resistance of glioblastoma stem cells under normoxia and hypoxia
    Cancer Research UK
    2016 - 2017
     
  • Radiotherapy Research Infrastructure
    Beatson Cancer Charity
    2016 - 2019
     
  • ISSF Catalyst: Integrative polyomics approach to identify metabolomic and genomic signatures of glioma stem cells for therapeutic intervention in glioblastoma
    Wellcome Trust
    2016 - 2016
     
  • PARADIGM-Trans: Sample collection associated with the PARADIGM Trial
    Cancer Research UK
    2015 - 2016
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2015 - 2016
     
  • SYSTEMS 2: A randomized Phase II trial of standard versus does escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
    Beatson Cancer Charity
    2015 - 2018
     
  • Overcoming treatment resistance and activating cell death in mesothelioma
    Beatson Cancer Charity
    2015 - 2016
     
  • Funding to support Clinical Oncology research
    NHS GGC
    2015 - 2015
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2015 - 2016
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2015 - 2016
     
  • Identification and validation of novel targets for overcoming radiation resistance of glioblastoma stem cells under normoxia and hypoxia
    Cancer Research UK
    2015 - 2016
     
  • Mitochondrial poisoning as a novel strategy to overcome radiation resistance of glioblastoma
    Scottish Executive Health Department
    2015 - 2017
     
  • Increasing Radiotherapy responsiveness of mesothelioma by activating tumour specific cell death.
    The Netherlands Cancer Institute
    2014 - 2016
     
  • SYSTEMS 2: A randomized Phase II trial of standard versus does escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
    June Hancock Mesothelioma Research Fund
    2014 - 2017
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2014 - 2015
     
  • Investigating the potential for synergistic radiosensitisation of bladder cancer by gemcitabine and the PARP inhibitor olaparib
    Cancer Research UK
    2014 - 2015
     
  • A Phase I study of Olaparib in Combination with Chemo-Radiation in Locally Advanced Pancreatic Cancer.
    Cancer Research UK
    2014 - 2017
     
  • Radiotherapy-Drug Combinations Technician
    The Beatson Oncology Centre Fund
    2014 - 2017
     
  • Developing and testing novel therapies targeting the invasive behaviour of human glioblastoma
    The Brain Tumour Charity
    2014 - 2017
     
  • Radiosensitisation of Glioblastoma multiforme (GBM) by development of a gold nanoparticle (AuNP) delivery system for siRNA silencing of ataxia telangiectasia mutated (Atm)
    Cancer Research UK
    2014 - 2016
     
  • Development Award: Measurement of Small Molecule Pharmacokinetics in invasive Regions of Glioblastoma
    Cancer Research UK
    2014 - 2016
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2014 - 2015
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2014 - 2015
     
  • Developing and testing novel therapies targeting the invasive behaviour of human glioblastoma
    NHS Greater Glasgow & Clyde
    2014 - 2017
     
  • DNA Damage Response in glioblastoma.
    Beatson Oncology Centre
    2013 - 2014
     
  • An examination of diagnostic and prognostic biomarkers in malignant pleural mesothelioma
    Scottish Executive Health Department
    2013 - 2016
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2013 - 2018
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2013 - 2014
     
  • Overcoming treatment resistance in glioblastoma multiforme by tumour specific inhibition of DNA repair
    Medical Research Council
    2013 - 2015
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2013 - 2014
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2013 - 2014
     
  • Investigation of [18F]-Fluciclatide as a PET imaging agent for imaging angiogenesis in Glioblastoma
    Cancer Research UK
    2012 - 2013
     
  • Comparative global transcriptome analysis of glioma stem like and bulk cells for identification of therapeutic targets
    Cancer Research UK
    2012 - 2013
     
  • Increasing Radiotherapy responsiveness of mesothelioma by activating tumour specific cell death.
    British Lung Foundation
    2012 - 2015
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2012 - 2013
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2012 - 2013
     
  • Molecular Imaging and Targeted Radionuclide Therapy for Cancer: Synthesis of a Novel Radiolabelled PARP-1 Inhibitor
    Cancer Research UK
    2010 - 2012
     
  • Overcoming treatment resistance in glioblastoma multiforme by tumour specific inhibition of DNA repair
    MRC
    2010 - 2014
     

Publications

List by: Type | Date

Jump to: 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
Number of items: 33.

2016

Gomez-Roman, N., Stevenson, K., Gilmour, L., Hamilton, G., and Chalmers, A. (2016) A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Neuro-Oncology, (doi:10.1093/neuonc/now164) (PMID:27576873) (Early Online Publication)

Lorimer, C. F., Saran, F., Chalmers, A. J., and Brock, J. (2016) Glioblastoma in the elderly - how do we choose who to treat? Journal of Geriatric Oncology, (doi:10.1016/j.jgo.2016.07.005) (PMID:27478132) (In Press)

Chalmers, A. J. (2016) Science in focus: combining radiotherapy with inhibitors of the DNA damage response. Clinical Oncology, 28(5), pp. 279-282. (doi:10.1016/j.clon.2016.01.035) (PMID:26920234)

Gomez-Roman, N., McGregor, F., Chalmers, A. J., and Plumb, J. (2016) Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. Oncotarget, 7, 16. (doi:10.18632/oncotarget.7998) (PMID:26967059)

Niyazi, M. et al. (2016) ESTRO-ACROP guideline 'target delineation of glioblastomas'. Radiotherapy and Oncology, 118(1), pp. 35-42. (doi:10.1016/j.radonc.2015.12.003) (PMID:26777122)

2015

Tardito, S. et al. (2015) Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology, 17(12), pp. 1556-1568. (doi:10.1038/ncb3272) (PMID:26595383)

Zmuda, F., Malviya, G., Blair, A., Boyd, M., Chalmers, A. J., Sutherland, A., and Pimlott, S. L. (2015) Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo. Journal of Medicinal Chemistry, 58(21), pp. 8683-8693. (doi:10.1021/acs.jmedchem.5b01324) (PMID:26469301)

Ahmed, S., Carruthers, R., Gilmour, L., Yildirim, S., Watts, C., and Chalmers, A. (2015) Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Research, 75(20), pp. 4416-4428. (doi:10.1158/0008-5472.can-14-3790) (PMID:26282173)

Mac Leod, N. et al. (2015) F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study. Reports of Radiotherapy and Oncology, 2(2), e3999. (doi:10.17795/rro-3999)

Carruthers, R., and Chalmers, A. (2015) Combination of PARP inhibitors with clinical radiotherapy. In: Curtin, N. J. and Sharma, R. A. (eds.) PARP Inhibitors for Cancer Therapy. Series: Cancer drug discovery and development, 5 (83). Springer International Publishing, pp. 533-551. ISBN 9783319141503 (doi:10.1007/978-3-319-14151-0_23)

MacLeod, N. et al. (2015) Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. Journal of Thoracic Oncology, 10(6), pp. 944-950. (doi:10.1097/JTO.0000000000000499) (PMID:25654216)

Ichim, G. et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Molecular Cell, 57(5), pp. 860-872. (doi:10.1016/j.molcel.2015.01.018) (PMID:25702873) (PMCID:PMC4352766)

Meisenberg, C., Gilbert, D. C., Chalmers, A., Haley, V., Gollins, S., Ward, S. E., and El-Khamisy, S. F. (2015) Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Molecular Cancer Therapeutics, 14(2), pp. 575-585. (doi:10.1158/1535-7163.MCT-14-0762) (PMID:25522766)

Carruthers, R., Ahmed, S. U., Strathdee, K., Gomez-Roman, N., Amoah-Buahin, E., Watts, C., and Chalmers, A. J. (2015) Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Molecular Oncology, 9(1), pp. 192-203. (doi:10.1016/j.molonc.2014.08.003)

Blair, A., Zmuda, F., Malviya, G., Chalmers, A. J., Dewar, D., Pimlott, S. L., and Sutherland, A. (2015) A novel 18F-labelled high affinity agent for PET imaging of the translocator protein. Chemical Science, 6(8), pp. 4772-4777. (doi:10.1039/C5SC01647A)

2014

Ajaz, M., Jefferies, S., Brazil, L., Watts, C., and Chalmers, A. (2014) Current and investigational drug strategies for glioblastoma. Clinical Oncology, 26(7), pp. 419-430. (doi:10.1016/j.clon.2014.03.012)

Mannino, M., Gomez-Roman, N., Hochegger, H., and Chalmers, A. J. (2014) Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics. Stem Cell Research, 13(1), pp. 135-143. (doi:10.1016/j.scr.2014.05.001) (PMID:24879067) (PMCID:PMC4085484)

Yahyanejad, S., Granton, P. V., Lieuwes, N. G., Gilmour, L., Dubois, L., Theys, J., Chalmers, A. J., Verhaegen, F., and Vooijs, M. (2014) Complementary use of bioluminescence imaging and contrast-enhanced micro-computed tomography in an orthotopic brain tumor model. Molecular imaging, 13, pp. 1-8. (PMID:25743108)

Smalley, S., Chalmers, A. J., and Morley, S. J. (2014) mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells. Molecular Cancer, 13(144), (doi:10.1186/1476-4598-13-144)

2013

Hellevik, T., Pettersen, I., Berg, V., Bruun, J., Bartnes, K., Busund, T.-L., Chalmers, A., Bremnes,, R., and Martinez-Zubiaurre, I. (2013) Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: potential impact on angiogenesis and tumor growth. Translational Onocology, 6(1), pp. 66-74.

2012

Alagoz, M., Gilbert, D.C., El-Khamisy, S., and Chalmers, A. (2012) DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Current Medicinal Chemistry, 19(23), pp. 3874-3885. (doi:10.2174/092986712802002590)

Ford, E., Catt, S., Chalmers, A., and Fallowfield, L. (2012) Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology, 14(4), pp. 392-404. (doi:10.1093/neuonc/nor229)

Gilbert, D.C., Chalmers, A.J., and El-Khamisy, S.F. (2012) Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. British Journal of Cancer, 106(1), pp. 18-24. (doi:10.1038/bjc.2011.498)

Hellevik, T. et al. (2012) Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiation Oncology, 7(59), (doi:10.1186/1748-717X-7-59)

2011

Mannino, M., and Chalmers, A. J. (2011) Radioresistance of glioma stem cells: Intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Molecular Oncology, 5(4), pp. 374-386. (doi:10.1016/j.molonc.2011.05.001)

Catt, S. L., Anderson, J. L., Chalmers, A. J., and Fallowfield, L. J. (2011) A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent. Journal of Evaluation in Clinical Practice, 17(1), pp. 1-6. (doi:10.1111/j.1365-2753.2009.01292.x)

2010

Chalmers, A. J., Lakshman, M., Chan, N., and Bristow, R. G. (2010) Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Seminars in Radiation Oncology, 20(4), pp. 274-281. (doi:10.1016/j.semradonc.2010.06.001)

Chalmers, A. J. (2010) Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 10(7), pp. 520-533. (doi:10.2174/187152010793498627)

Löser, D. A., Shibata, A., Shibata, A. K., Woodbine, L. J., Jeggo, P. A., and Chalmers, A. J. (2010) Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Molecular Cancer Therapeutics, 9(6), pp. 1775-1787. (doi:10.1158/1535-7163.MCT-09-1027)

Chalmers, A.J. (2010) Evaluating novel radiation techniques for the treatment of cerebral metastases. British Journal of Radiology, 83(986), pp. 98-100. (doi:10.1259/bjr/15790337)

2009

Chalmers, A.J., Ruff, E.M., Martindale, C., Lovegrove, N., and Short, S.C. (2009) Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. International Journal of Radiation Oncology, Biology, Physics, 75(5), pp. 1511-1519. (doi:10.1016/j.ijrobp.2009.07.1703)

Dungey, F.A., Caldecott, K.W., and Chalmers, A.J. (2009) Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Molecular Cancer Therapeutics, 8(8), pp. 2243-2245. (doi:10.1158/1535-7163.MCT-09-0201)

2008

Dungey, F.A., Löser, D.A., and Chalmers, A.J. (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. International Journal of Radiation Oncology, Biology, Physics, 72(4), pp. 1188-1197. (doi:10.1016/j.ijrobp.2008.07.031)

This list was generated on Wed Sep 28 05:57:00 2016 BST.
Number of items: 33.

Articles

Gomez-Roman, N., Stevenson, K., Gilmour, L., Hamilton, G., and Chalmers, A. (2016) A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Neuro-Oncology, (doi:10.1093/neuonc/now164) (PMID:27576873) (Early Online Publication)

Lorimer, C. F., Saran, F., Chalmers, A. J., and Brock, J. (2016) Glioblastoma in the elderly - how do we choose who to treat? Journal of Geriatric Oncology, (doi:10.1016/j.jgo.2016.07.005) (PMID:27478132) (In Press)

Chalmers, A. J. (2016) Science in focus: combining radiotherapy with inhibitors of the DNA damage response. Clinical Oncology, 28(5), pp. 279-282. (doi:10.1016/j.clon.2016.01.035) (PMID:26920234)

Gomez-Roman, N., McGregor, F., Chalmers, A. J., and Plumb, J. (2016) Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. Oncotarget, 7, 16. (doi:10.18632/oncotarget.7998) (PMID:26967059)

Niyazi, M. et al. (2016) ESTRO-ACROP guideline 'target delineation of glioblastomas'. Radiotherapy and Oncology, 118(1), pp. 35-42. (doi:10.1016/j.radonc.2015.12.003) (PMID:26777122)

Tardito, S. et al. (2015) Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology, 17(12), pp. 1556-1568. (doi:10.1038/ncb3272) (PMID:26595383)

Zmuda, F., Malviya, G., Blair, A., Boyd, M., Chalmers, A. J., Sutherland, A., and Pimlott, S. L. (2015) Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo. Journal of Medicinal Chemistry, 58(21), pp. 8683-8693. (doi:10.1021/acs.jmedchem.5b01324) (PMID:26469301)

Ahmed, S., Carruthers, R., Gilmour, L., Yildirim, S., Watts, C., and Chalmers, A. (2015) Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Research, 75(20), pp. 4416-4428. (doi:10.1158/0008-5472.can-14-3790) (PMID:26282173)

Mac Leod, N. et al. (2015) F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study. Reports of Radiotherapy and Oncology, 2(2), e3999. (doi:10.17795/rro-3999)

MacLeod, N. et al. (2015) Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. Journal of Thoracic Oncology, 10(6), pp. 944-950. (doi:10.1097/JTO.0000000000000499) (PMID:25654216)

Ichim, G. et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Molecular Cell, 57(5), pp. 860-872. (doi:10.1016/j.molcel.2015.01.018) (PMID:25702873) (PMCID:PMC4352766)

Meisenberg, C., Gilbert, D. C., Chalmers, A., Haley, V., Gollins, S., Ward, S. E., and El-Khamisy, S. F. (2015) Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Molecular Cancer Therapeutics, 14(2), pp. 575-585. (doi:10.1158/1535-7163.MCT-14-0762) (PMID:25522766)

Carruthers, R., Ahmed, S. U., Strathdee, K., Gomez-Roman, N., Amoah-Buahin, E., Watts, C., and Chalmers, A. J. (2015) Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Molecular Oncology, 9(1), pp. 192-203. (doi:10.1016/j.molonc.2014.08.003)

Blair, A., Zmuda, F., Malviya, G., Chalmers, A. J., Dewar, D., Pimlott, S. L., and Sutherland, A. (2015) A novel 18F-labelled high affinity agent for PET imaging of the translocator protein. Chemical Science, 6(8), pp. 4772-4777. (doi:10.1039/C5SC01647A)

Ajaz, M., Jefferies, S., Brazil, L., Watts, C., and Chalmers, A. (2014) Current and investigational drug strategies for glioblastoma. Clinical Oncology, 26(7), pp. 419-430. (doi:10.1016/j.clon.2014.03.012)

Mannino, M., Gomez-Roman, N., Hochegger, H., and Chalmers, A. J. (2014) Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics. Stem Cell Research, 13(1), pp. 135-143. (doi:10.1016/j.scr.2014.05.001) (PMID:24879067) (PMCID:PMC4085484)

Yahyanejad, S., Granton, P. V., Lieuwes, N. G., Gilmour, L., Dubois, L., Theys, J., Chalmers, A. J., Verhaegen, F., and Vooijs, M. (2014) Complementary use of bioluminescence imaging and contrast-enhanced micro-computed tomography in an orthotopic brain tumor model. Molecular imaging, 13, pp. 1-8. (PMID:25743108)

Smalley, S., Chalmers, A. J., and Morley, S. J. (2014) mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells. Molecular Cancer, 13(144), (doi:10.1186/1476-4598-13-144)

Hellevik, T., Pettersen, I., Berg, V., Bruun, J., Bartnes, K., Busund, T.-L., Chalmers, A., Bremnes,, R., and Martinez-Zubiaurre, I. (2013) Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: potential impact on angiogenesis and tumor growth. Translational Onocology, 6(1), pp. 66-74.

Alagoz, M., Gilbert, D.C., El-Khamisy, S., and Chalmers, A. (2012) DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Current Medicinal Chemistry, 19(23), pp. 3874-3885. (doi:10.2174/092986712802002590)

Ford, E., Catt, S., Chalmers, A., and Fallowfield, L. (2012) Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology, 14(4), pp. 392-404. (doi:10.1093/neuonc/nor229)

Gilbert, D.C., Chalmers, A.J., and El-Khamisy, S.F. (2012) Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. British Journal of Cancer, 106(1), pp. 18-24. (doi:10.1038/bjc.2011.498)

Hellevik, T. et al. (2012) Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiation Oncology, 7(59), (doi:10.1186/1748-717X-7-59)

Mannino, M., and Chalmers, A. J. (2011) Radioresistance of glioma stem cells: Intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Molecular Oncology, 5(4), pp. 374-386. (doi:10.1016/j.molonc.2011.05.001)

Catt, S. L., Anderson, J. L., Chalmers, A. J., and Fallowfield, L. J. (2011) A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent. Journal of Evaluation in Clinical Practice, 17(1), pp. 1-6. (doi:10.1111/j.1365-2753.2009.01292.x)

Chalmers, A. J., Lakshman, M., Chan, N., and Bristow, R. G. (2010) Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Seminars in Radiation Oncology, 20(4), pp. 274-281. (doi:10.1016/j.semradonc.2010.06.001)

Chalmers, A. J. (2010) Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 10(7), pp. 520-533. (doi:10.2174/187152010793498627)

Löser, D. A., Shibata, A., Shibata, A. K., Woodbine, L. J., Jeggo, P. A., and Chalmers, A. J. (2010) Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Molecular Cancer Therapeutics, 9(6), pp. 1775-1787. (doi:10.1158/1535-7163.MCT-09-1027)

Chalmers, A.J. (2010) Evaluating novel radiation techniques for the treatment of cerebral metastases. British Journal of Radiology, 83(986), pp. 98-100. (doi:10.1259/bjr/15790337)

Chalmers, A.J., Ruff, E.M., Martindale, C., Lovegrove, N., and Short, S.C. (2009) Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. International Journal of Radiation Oncology, Biology, Physics, 75(5), pp. 1511-1519. (doi:10.1016/j.ijrobp.2009.07.1703)

Dungey, F.A., Caldecott, K.W., and Chalmers, A.J. (2009) Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Molecular Cancer Therapeutics, 8(8), pp. 2243-2245. (doi:10.1158/1535-7163.MCT-09-0201)

Dungey, F.A., Löser, D.A., and Chalmers, A.J. (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. International Journal of Radiation Oncology, Biology, Physics, 72(4), pp. 1188-1197. (doi:10.1016/j.ijrobp.2008.07.031)

Book Sections

Carruthers, R., and Chalmers, A. (2015) Combination of PARP inhibitors with clinical radiotherapy. In: Curtin, N. J. and Sharma, R. A. (eds.) PARP Inhibitors for Cancer Therapy. Series: Cancer drug discovery and development, 5 (83). Springer International Publishing, pp. 533-551. ISBN 9783319141503 (doi:10.1007/978-3-319-14151-0_23)

This list was generated on Wed Sep 28 05:57:00 2016 BST.